Vertex Co-op - Enterprise Applications & Analytics
About the job
- Enrolled in an undergraduate or graduate program and majoring in Project Management, Human Resources, or a related field
- Legal authorization to work in the United States, now and in the future. Please note that Vertex does not provide sponsorship for internships or entry level roles within this part of the organization.
- You must be enrolled in an advanced degree program if graduating before December 2026
- You must be available to work full-time, 40 hours per week from July – December 2026
- Collaborate with team members to deliver high-quality product features.
- Conduct research and analysis to support product development and decision-making.
- Assist in testing and quality assurance to ensure product reliability and performance.
- Document processes, workflows, and technical specifications to support team operations.
- Facilitate daily stand-up meetings to ensure team alignment and progress tracking.
- Assist in organizing and scheduling Agile ceremonies, including sprint planning, reviews, and retrospectives.
- Collaborate with the Product Owners to maintain and prioritize the product backlog.
- Support the team in identifying and addressing blockers to maintain workflow efficiency.
- Promote Agile best practices and foster a culture of collaboration and continuous improvement.
- Track and document sprint progress using tools like sprint boards and generate relevant reports.
Job Description
Kickstart Your Career at Vertex!
Are you ready to make a real impact? At Vertex, our mission is to tackle serious diseases and to change lives, for the better, for the future. Our aim is to give you the skills, insights, and career guidance to be an important part of that future; to turn your potential into progression. As a Vertex intern or co-op, you’ll work on meaningful projects, collaborate with talented teams, and learn from industry leaders. We’re passionate about innovation, inclusion, and supporting your growth—inside and outside the lab.
Why Vertex?
- Real Projects: You’ll work on assignments that make a real impact, not just busy work.
- Mentorship & Networking: Connect with leaders and peers who want to see you succeed through professional networks, connections, and collaborations that will shape your longer-term career.
- Flexible & Supportive: We offer flexible work options with Flex @ Vertex and prioritize your wellbeing.
- Inclusive Culture: Collaboration and inclusion are embedded in everything we do.
- Career Launchpad: Build skills, explore career paths, and get guidance for your future career.
Ready to apply? Submit your application and let’s turn possibilities into reality!
Your Impact
The Vertex Enterprise Applications and Analytics co-op program is a 6-month experiential training program for students currently working towards an undergraduate or advanced degree in Project Management or Human Resources-related fields of study. If you are passionate, collaborative, and growth-minded, a co-op at Vertex will help you gain meaningful experience in our DTE functional areas and serve as a launchpad for your career.
The application deadline for this co-op is April 3rd. Please note that Vertex reviews applications on a rolling basis and reserves the right to close this job posting prior to the listed deadline. Applicants can expect to receive an update about their application before or shortly after the application deadline.
Important Notice Regarding Internship and Co-op Inquiries
At Vertex Pharmaceuticals, we are committed to providing a fair and structured recruitment process for all students interested in internship and co-op opportunities. To ensure consistency and equity, all student applications must go through our Early Talent Acquisition Team.
Due to the high volume of interest, we are unable to respond to individual solicitation. Direct solicitation to Vertex employees- including senior leaders via email will result in removal from the recruiting process.
We appreciate your enthusiasm and interest in Vertex. To be considered for internship or co-op roles, please apply directly through our official application channels. (https://www.vrtx.com/careers/career-growth-and-opportunities/co-ops/)
Thank you for respecting our process and helping us maintain a fair experience for all candidates.
What you will be doing:
As a Co-op Student in Application & Product Management, you’ll work closely with the DTE team, developers and designers to support the entire product lifecycle for HR applications. You’ll help gather user feedback, analyze product performance, assist with feature planning, and contribute to improving our applications. This role offers exposure to both the strategic and tactical aspects of product management, from understanding customer needs to supporting product launches.
You’ll participate in product meetings, conduct user research, help maintain product documentation, and use data to inform product decisions. We’ll also ensure you have mentorship and learning opportunities throughout your term to develop skills that will serve you well in your career.
Core Responsibilities
- Collaborate with team members to deliver high-quality product features.
- Conduct research and analysis to support product development and decision-making.
- Assist in testing and quality assurance to ensure product reliability and performance.
- Document processes, workflows, and technical specifications to support team operations.
Scrum Responsibilities
- Facilitate daily stand-up meetings to ensure team alignment and progress tracking.
- Assist in organizing and scheduling Agile ceremonies, including sprint planning, reviews, and retrospectives.
- Collaborate with the Product Owners to maintain and prioritize the product backlog.
- Support the team in identifying and addressing blockers to maintain workflow efficiency.
- Promote Agile best practices and foster a culture of collaboration and continuous improvement.
- Track and document sprint progress using tools like sprint boards and generate relevant reports.
General Goals
Understand our product portfolio, and user base.
- Learn the product development process and key tools/systems.
- Build relationships with team members across product, engineering, and design.
Deliverable Goals
- Develop technical and professional skills through hands-on project work and mentorship.
- Gain foundational knowledge of Agile and Scrum methodologies.
- Build expertise in backlog management, prioritization, and sprint planning.
- Understand the role of agile in driving team success and continuous improvement.
Professional Development Goals
- Actively participate in product team meetings and retrospectives.
- Seek and apply regular feedback from your manager.
- Expand your professional network through informational interviews.
- Deliver a final presentation summarizing your contributions and key learnings.
What you will need to succeed:
- Enrolled in an undergraduate or graduate program and majoring in Project Management, Human Resources, or a related field
- Legal authorization to work in the United States, now and in the future. Please note that Vertex does not provide sponsorship for internships or entry level roles within this part of the organization.
- You must be enrolled in an advanced degree program if graduating before December 2026
- You must be available to work full-time, 40 hours per week from July – December 2026
Program Details:
- Full-time, paid internship $20.00 – 32.00 USD/hour
- Program Dates: July – December 2026
- Application Deadline: April 3rd, 2026
At Vertex, we believe that when you feel your best, you can perform at your best. That’s why our US benefits and global well-being resources are designed to support you.
• Free 24/7 onsite gym access and free access to group exercise classes
• Subsidized commuter benefits- transit and parking
• Provided meals—free breakfast daily!
• Career development opportunities and events, including C Suite engagement
• Social events—both intern-only and company-wide
• Location-specific perks and extras!
• Recognition of National Intern Day
Our Ways of Working
Flex Designation: Hybrid-Eligible Or On-Site Eligible
Flex Eligibility Status:
In this Hybrid-Eligible role, you can choose to be designated as:
1. Hybrid: work remotely up to two days per week; or select
2. On-Site: work five days per week on-site with ad hoc flexibility.
Note: The Flex status for this position is subject to Vertex’s Policy on Flex @ Vertex Program and may be changed at any time.
Equal Opportunities
Vertex is committed to equal employment opportunity and non-discrimination for all employees and qualified applicants without regard to a person's race, color, sex, gender identity or expression, age, religion, national origin, ancestry, ethnicity, disability, veteran status, genetic information, sexual orientation, marital status, or any characteristic protected under applicable law. Vertex is an E-Verify Employer in the United States. Vertex will make reasonable accommodations for qualified individuals with known disabilities, in accordance with applicable law.
Vertex is an E-Verify Employer in the United States. We consider qualified applicants regardless of criminal histories, consistent with legal requirements.
Accessibility & Accommodations
We're focused on attracting, retaining, developing, and advancing our employees. By cultivating a workplace that values diverse experiences, backgrounds, and ideas, we create an environment where every employee can contribute their best. Vertex is committed to offering reasonable accommodations to qualified job applicants with disabilities. Any applicant requiring an accommodation in connection with the hiring process and/or to perform the essential functions of the position for which the applicant has applied should make a request to the recruiter or hiring manager, or contact Talent Acquisition at [email protected]
Export Control Notice
This position may involve access to technology or data that is subject to U.S. export control laws, including the Export Administration Regulations (EAR). As such, employment is contingent upon the applicant's ability to access export-controlled information in accordance with U.S. law. Due to the nature of the work and regulatory requirements, only individuals who qualify as U.S. persons (citizens, permanent residents, asylees, or refugees) are eligible for this position. For this role, Vertex is unable to sponsor non-U.S. persons to apply for an export control license.
This job posting is for a temporary role with a third-party agency partner that provides services to Vertex. The individual selected for this role will be offered the role as an employee of that third-party agency; compensation, medical benefits, fringe benefits and other terms and conditions of employment shall be presented by the third-party agency upon offer.
Pay Range:
$0 - $0Disclosure Statement:
The range provided is based on what we believe is a reasonable estimate for the base salary pay range for this job at the time of posting. This role is eligible for an annual bonus and annual equity awards. Some roles may also be eligible for overtime pay, in accordance with federal and state requirements. Actual base salary pay will be based on a number of factors, including skills, competencies, experience, and other job-related factors permitted by law.
At Vertex, our Total Rewards offerings also include inclusive market-leading benefits to meet our employees wherever they are in their career, financial, family and wellbeing journey while providing flexibility and resources to support their growth and aspirations. From medical, dental and vision benefits to generous paid time off (including a week-long company shutdown in the Summer and the Winter), educational assistance programs including student loan repayment, a generous commuting subsidy, matching charitable donations, 401(k) and so much more.
Company Information
Vertex is a global biotechnology company that invests in scientific innovation.
Vertex is committed to equal employment opportunity and non-discrimination for all employees and qualified applicants without regard to a person's race, color, sex, gender identity or expression, age, religion, national origin, ancestry, ethnicity, disability, veteran status, genetic information, sexual orientation, marital status, or any characteristic protected under applicable law. Vertex is an E-Verify Employer in the United States. Vertex will make reasonable accommodations for qualified individuals with known disabilities, in accordance with applicable law.
Any applicant requiring an accommodation in connection with the hiring process and/or to perform the essential functions of the position for which the applicant has applied should make a request to the recruiter or hiring manager, or contact Talent Acquisition at [email protected]
About the company
Vertex Pharmaceuticals develops medicines for serious diseases, with a focus on cystic fibrosis. It conducts extensive research and partners with other biotech firms to discover and develop new therapies, including ex vivo engineered cell treatments. Its products, such as ivacaftor, treat cystic fibrosis and other therapies undergo clinical testing to expand the pipeline. Revenue comes from selling approved drugs and from licensing and collaboration agreements. The company distinguishes itself through deep R&D investment, strategic partnerships, and a global reach aimed at addressing unmet medical needs. The overall goal is to bring effective new drugs to patients worldwide and improve outcomes and quality of life.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Boston, MA
Founded
1989
Get referred to Vertex Pharmaceuticals
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue reached $3.33 billion, and management raised full-year guidance to $13.2 billion.
- Inaxaplin showed -42.7% UACR reduction on September 22, 2026, advancing AMKD expansion.
- Povetacicept faces November 30, 2026 FDA review after strong IgAN proteinuria reductions.
What critics are saying
- Vertex lost its Lupin ivacaftor patent case on August 24, 2026, weakening exclusivity.
- The September 4, 2026 D.C. Circuit ruling limited Vertex's fertility-support program for Casgevy.
- If CF generics spread before 2029, Vertex's cash engine shrinks faster than new pillars mature.
What makes Vertex Pharmaceuticals unique
- Vertex owns the dominant cystic fibrosis franchise, treating about 95% of core-market patients.
- Casgevy gives Vertex first-mover gene-editing credibility in sickle cell and beta thalassemia.
- Crinetics adds PALSONIFY and atumelnant, expanding Vertex into endocrine diseases on September 1, 2026.
Help us improve and share your feedback! Did you find this helpful?
Benefits
- Hybrid Work Options
Growth & Insights and Company News
6 month growth
8%1 year growth
7%2 year growth
7%Vertex Pharmaceuticals raised its full-year revenue guidance to $13.15 billion–$13.25 billion after third-quarter revenue rose 12% year over year. The previous range was $13.1 billion to $13.2 billion. The outlook includes $40 million–$50 million from Crinetics, which Vertex acquired in September. Projected operating expenses rose to about $6 billion, up from $5.65 billion–$5.75 billion, reflecting roughly $250 million of Crinetics costs. Newer products gained ground. ALYFTREK sales reached $706 million, CASGEVY revenue rose 30% sequentially to $99 million, and JOURNAVX brought in $58 million. The US Food and Drug Administration is due to decide on povetacicept for IgA nephropathy by November 30.
StockStory has picked three large-cap stocks it says have solid fundamentals: Boeing, Trane Technologies, and Vertex Pharmaceuticals. Boeing (market cap $136.8 billion) is part of a duopoly in commercial aircraft. Unit sales grew 51.8% on average over two years, and earnings per share rose 60.5% annually. Its shares trade at $170.95, or 209.5x forward P/E. Trane Technologies ($94.85 billion) grew revenue 11.1% annually over five years, with earnings per share up 20.5% a year. Its shares trade at $434.31, or 26.1x forward P/E. Vertex Pharmaceuticals ($136.9 billion) posted 13.5% annual sales growth over five years and a return on invested capital of 29.5%. Its shares trade at $552.80, or 27.5x forward P/E.
UK Budget light on life sciences but more doors open for biotech startups. The UK Autumn Budget offered little in the way of new measures specifically for the life sciences sector, though incentives for early-stage businesses could help certain biotechs looking to establish themselves in Britain. At the heart of the government's aim is a new tax relief for founders looking to scale their companies in the UK. Called "Founders Relief", the framework will offer eligible founders of high-growth, innovative companies a reduced 10% rate of Capital Gains Tax on up to £10m of lifetime gains. This marks a steep markdown from the standard rate of 18%. There are several scaling, innovation, and business activity criteria that need to be met for a founder to qualify for the scheme. Reacting to the Budget, BioIndustry Association (BIA)'s CEO Chris Molloy said: "Although there is broad merit in the Founders' Relief, the initial inclusion criteria are more relevant to high street businesses, not high-tech, VC-backed biotechs. We shall be working with members and Treasury during the next month's consultation period to ensure the needs of biotech founders are well understood." Gail Vallis, corporate and life sciences partner at law firm Gardner Leader, disagreed, commenting: "This is great news for those taking substantial risks in setting up promising new companies, especially at the cutting edge of R&D in areas such as life sciences, but misses the mark for those who have taken the same risks on an existing early-stage company or those that have saved a struggling business. It will be very interesting to see what the qualifying conditions will be for a company to be considered high growth or innovative." Alongside the relief, people starting a business will have their trading allowance tripled to £3,000. The government said it would also improve venture capital (VC) schemes and simplify access to R&D tax reliefs, as well as making it easier for employees to own shares in the companies they work for. Chancellor John Healy announced a £20.4bn boost to the National Wealth Fund and British Business Bank (BBB). The latter is a key financing vehicle for British small and medium-sized enterprises (SMEs). Molley said: "We are pleased to see the Chancellor fuel the life sciences innovation engine through an increased and front-loaded budget for BBB that will back funders and companies across biotech and dual-use technologies." This Budget also brings new legislation to make non-compete clauses less of a barrier for startups and scaling firms to attract talent, with guidance slated for release in early 2027. The government said the steps will help achieve its ambition in making the UK "the best place in the world to start a business, scale it, and stay here for the long term". One of the few life science-specific announcements was a series of public-private investments worth over £1bn, though only £70m of this was backed by government grants. US biopharma Vertex Pharmaceuticals is opening a new £300m facility in Oxford, medtech specialist Convatec is investing over £500m over the next decade in a new R&D hub in Manchester, and CDMO Kindeva is pumping £200m at its base in Loughborough. Vallis commented: "£70m of grant funding is fantastic too, but that won't go far for companies looking to take their drugs through clinical trials. Work is still required to attract investors to invest more widely across the sector." The Budget comes at a time of renewed hope in the UK's biotech sector. A report released this week by the BioIndustry Association (BIA) has found that the UK is likely on track to post its best year since 2021 for biotech VC acquisition. As the British life sciences funding scene looks to get back to winning ways, M&A has already seen notable success so far this year, with three acquisition deals above $1bn of British biotechs in 2026. The most expensive of these was Eli Lilly purchasing sleep drug biotech Centessa Pharmaceuticals for up to $7.8bn in June. However, the wait for a biotech listing in the UK this year goes on, reflecting hesitancy around the nation's wider macroeconomic health. Give your business an edge with its leading industry insights.
UK budget includes £1bn biopharma investment package. Among the highlights of UK Chancellor John Healey's first Budget was more than £1 billion in investment by Convatec, Vertex Pharmaceuticals, and Kindeva, supported by £70 million in government funding. Medtech firm Convatec has agreed to invest more than £500 million over the next 10 years to build an R&D hub in Manchester for products used in wound care, ostomy, continence, and infusion care products, which is due to open in early 2028. The facility will be located at the Citylabs SciTech campus and will house roughly 200 workers, with some transitioning from Convatec's older Deeside site, alongside newly created local positions. Meanwhile, Vertex has pledged over £300 million to develop a brand-new facility in Oxford focusing on medicines research and pharmaceutical innovation, and drug delivery specialist Kindeva is planning to spend £200 million in Loughborough to boost local drug delivery development and manufacturing capabilities Overall, it is expected that the investments will support more than 1,000 jobs across regional innovation hubs, according to Kenan Poleo, director of the UK Office for Life Sciences (OLS). "These numbers matter. But what matters even more is what sits behind them: companies choosing the UK to invest, innovate and grow, talented people getting high-quality jobs, and patients ultimately benefiting from new treatments," he added. "Lots still to do, but today is another important vote of confidence in UK life sciences." The Association of the British Pharmaceutical Industry (ABPI) welcomed the investment, along with the government's maintaining the corporation tax cap at 25% and maintaining full expensing - a tax relief that allows companies to deduct 100% of their spending on qualifying plant and machinery from taxable profits in the year the purchase is made. The trade body said it was also pleased by new powers under the Regulation for Growth Bill to test innovative products, including medicines and medical devices, in a supervised, time-limited, live-market environment. VAT move on free medicines applauded. Another key development was the closure of a VAT loophole that has made it difficult for pharma manufacturers to make medicines available to patients for free. The longstanding issue was the policy of HM Revenue and Customs (HMRC) to treat free-of-charge medicine supplies as "deemed supplies" or barter transactions and so subject to a 20% VAT charge, even though no money changed hands. That means that, until now, companies could face a VAT bill on medicines they provided without receiving any payment. Drugmakers mainly provide drugs for free to patients in the context of early access programmes for those that address an unmet clinical need, compassionate use for patients who have exhausted other treatment options, or post-trial care that plugs the gap between the end of studies and a medicine becoming approved and funded by the NHS. In some cases, companies agree to make a medicine available for free to the health service while further evidence of benefit in real-world settings is gathered. "Removing the VAT charge on medicines that companies provide free of charge is a significant win for patients, lifting a barrier to access, protecting continuity of care and supporting the clinical research that brings new treatments to the UK," said Joe Edwards, executive director for UK competitiveness at the ABPI. "We support this measure, which follows sustained work by patient groups, the ABPI and our members to inform this change," he added. "We will keep working together to ensure the relief is simple to use and covers the full range of programmes that matters to patients." 29 October, 2026
£300m Oxford biotech facility among Budget initiatives unveiled for South East. 28 Oct 2026, 15:59 A "cautious" first Budget from the Chancellor nonetheless featured a number of developments for the South East - including major funding for biotech, where the region excels. This year's full Budget document included news that American biotech Vertex Pharmaceuticals will invest more than £300m in a new 155,000 sq ft research facility at Harwell Campus in Oxfordshire. Construction of the facility, which is hoped will help accelerate the discovery of transformative medicines, is slated to begin in early 2027 and will support more than 200 jobs. The initiative was one of three public-private investments unveiled in the Budget, totalling more than £1bn and backed by almost £70m in grant funding. The Oxford-Cambridge Growth Corridor, much touted over the past year, was given another nod as the government confirmed it would pilot a new financing model for the Greater Cambridge Development Corporation, "giving it direct access to government finance for land assembly and to invest alongside private partners". A consultation is to be launched on a development corporation in Oxford "by the end of the year", with a similar pilot planned for the city. The Chancellor also pledged more than £75m to the CoSTAR network of labs anchored in Buckinghamshire and Surrey as well as Yorkshire, Dundee and Belfast. There was no news in the Budget on a third runway at Heathrow Airport as "the government works at pace to consider responses to the consultation", with an update promised "as soon as possible". Meanwhile, debt relief of £500m from the Public Works Loan Board (PWLB) was confirmed for the beleaguered Woking Borough Council.